agilon health (AGL) 10-Q 9 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 01, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	AGL
Entity Registrant Name	agilon health, inc.
Entity Central Index Key	0001831097
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common stock, $0.01 par value
Security Exchange Name	NYSE
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6210 E Hwy 290
Entity Address, Address Line Two	Suite 450
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78723
City Area Code	(562)
Local Phone Number	256-3800
Entity File Number	001-40332
Entity Tax Identification Number	37-1915147
Entity Common Stock, Shares Outstanding		414,833,009
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents		$ 394,190	$ 497,070
Restricted cash and equivalents	[1]	10,204	10,610
Marketable securities		422,492	411,901
Receivables, net		1,004,856	497,574
Prepaid expenses and other current assets, net		44,697	34,119
Total current assets		1,876,439	1,451,274
Property and equipment, net		22,132	20,050
Intangible assets, net		92,712	67,680
Goodwill		62,140	41,540
Other assets, net		116,846	116,924
Total assets		2,170,269	1,697,468
Current liabilities:
Medical claims and related payables		745,557	346,727
Accounts payable and accrued expenses		222,052	183,364
Current portion of long-term debt		5,000	5,000
Total current liabilities		972,609	535,091
Long-term debt, net of current portion		37,249	38,482
Other liabilities		78,571	83,286
Total liabilities		1,088,429	656,859
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.01 par value: 2,000,000 shares authorized; 414,465 and 412,385 shares issued and outstanding, respectively		4,145	4,124
Additional paid-in capital		2,130,126	2,106,886
Accumulated deficit		(1,048,208)	(1,064,230)
Accumulated other comprehensive income (loss)		(3,549)	(5,560)
Total agilon health, inc. stockholders' equity (deficit)		1,082,514	1,041,220
Noncontrolling interests		(674)	(611)
Total stockholders’ equity (deficit)		1,081,840	1,040,609
Total liabilities and stockholders' equity (deficit)		$ 2,170,269	$ 1,697,468
[1] Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	414,465,000	412,385,000
Common stock, shares outstanding	414,465,000	412,385,000
Assets	$ 2,170,269	$ 1,697,468
Liabilities	1,088,429	656,859
Variable Interest Entity, Primary Beneficiary
Assets	1,180,000	703,300
Liabilities	$ 897,700	$ 462,400

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenues	$ 1,136,147	$ 653,445
Expenses:
Medical services expense	972,827	566,208
Other medical expenses	86,024	44,773
General and administrative (including noncash stock-based compensation expense of $13,672 and $3,970, respectively)	66,846	39,834
Depreciation and amortization	4,189	3,373
Total expenses	1,129,886	654,188
Income (loss) from operations	6,261	(743)
Other income (expense):
Other income (expense), net	9,472	2,269
Interest expense	(1,533)	(871)
Income (loss) before income taxes	14,200	655
Income tax benefit (expense)	1,759	71
Income (loss) from continuing operations	15,959	726
Total discontinued operations	0	429
Discontinued operations:
Net income (loss)	15,959	1,155
Noncontrolling interests' share in (earnings) loss	63	75
Net income (loss) attributable to common shares	$ 16,022	$ 1,230
Net income (loss) per common share, basic and diluted
Net income (loss) per common share from continuing operations, basic	$ 0.04	$ 0
Net income (loss) per common share from continuing operations, diluted	0.04	0
Net income (loss) per common share from discontinued operations, basic	0	0
Net income (loss) per common share from discontinued operations, basic	$ 0	$ 0
Weighted average shares outstanding - basic	413,136	401,964
Weighted average shares outstanding - diluted	426,586	424,065
Medical Services Revenue
Revenues:
Total revenues	$ 1,134,830	$ 652,423
Other Operating Revenue
Revenues:
Total revenues	$ 1,317	$ 1,022

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
General And Administrative Including Non Cash Stock-based Compensation Expense	$ 13,672	$ 3,970

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 15,959	$ 1,155
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities, net of tax	1,896	0
Foreign currency translation adjustment	115	0
Total comprehensive income (loss)	17,970	1,155
Comprehensive (income) loss attributable to noncontrolling interests	63	75
Total comprehensive income (loss) attributable to agilon health, inc.	$ 18,033	$ 1,230

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	AOCI Attributable to Parent [Member]	Noncontrolling Interests
Beginning balance at Dec. 31, 2021	$ 1,091,596	$ 4,001	$ 2,045,572	$ (957,677)		$ (300)
Beginning balance, shares at Dec. 31, 2021		400,095
Net income (loss)	1,155			1,230		(75)
Exercise of stock options and other, net	14,756	$ 56	14,700
Exercise of stock options and other, net, shares		5,632
Stock-based compensation expense	3,970		3,970
Ending balance at Mar. 31, 2022	1,111,477	$ 4,057	2,064,242	(956,447)		(375)
Ending balance, shares at Mar. 31, 2022		405,727
Beginning balance at Dec. 31, 2022	$ 1,040,609	$ 4,124	2,106,886	(1,064,230)	$ (5,560)	(611)
Beginning balance, shares at Dec. 31, 2022	412,385,000	412,385
Net income (loss)	$ 15,959			16,022		(63)
Exercise of stock options and other, net	9,617	$ 20	9,597
Exercise of stock options and other, net, shares		2,002
Other comprehensive income (loss)	$ 2,011				2,011
Costs of RSU Vestings, Shares		79
Costs of RSU Vestings		$ 1	$ (1)
Shares withheld related to net share settlement, Shares		(1)
Shares withheld related to net share settlement	(28)		(28)
Stock-based compensation expense	$ 13,672		$ 13,672
Ending balance at Mar. 31, 2023	$ 1,081,840	$ 4,145	$ 2,130,126	$ (1,048,208)	$ (3,549)	$ (674)
Ending balance, shares at Mar. 31, 2023	414,465,000	414,465

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ 15,959	$ 1,155
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,189	3,373
Stock-based compensation expense	13,672	3,970
Loss (Income) from equity method investments	(1,376)	(2,033)
Other noncash items	(1,785)	556
Changes in operating assets and liabilities	(91,470)	(30,254)
Net cash provided by (used in) operating activities	(60,811)	(23,233)
Cash flows from investing activities:
Purchase of property and equipment, net	(3,717)	(4,049)
Purchase of intangible assets	0	(1,000)
Investment in loans receivable and other	(1,301)	(4,503)
Investments in marketable debt securities	(29,969)	0
Proceeds from maturities and sales of marketable securities and other	28,540	683
Net cash paid in business combination	(44,367)	0
Net cash provided by (used in) investing activities	(50,814)	(8,869)
Cash flows from financing activities:
Proceeds from other equity issuances, net	9,589	14,756
Repayments of long-term debt	(1,250)	(1,250)
Net cash provided by (used in) financing activities	8,339	13,506
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents	(103,286)	(18,596)
Cash, cash equivalents and restricted cash and equivalents, beginning of period	507,680	1,054,820
Cash, cash equivalents and restricted cash and equivalents, end of period	$ 404,394	$ 1,036,224

Business

Business	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Business	NOTE 1. Business Description of Business agilon health, inc., through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of March 31, 2023, the Company, through its contracted physician networks, provided care to approximately 402,200 Medicare Advantage members enrolled with private health plans. Beginning January 1, 2023, the Company expanded its operations into: (i) Portland, Maine, (ii) St. Paul, Minnesota, (iii) Detroit, Michigan, (iv) Charleston, South Carolina; (v) Statesville, North Carolina; and (vi) Jackson, Tennessee, along with additional partnerships in the Company’s existing Texas markets. See Note 14 for additional discussions related to the Company’s involvement with VIEs. The Company’s largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (“CD&R”), a private equity firm. All funds affiliated with CD&R are considered related parties.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and both joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. Use of Estimates Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and valuation of long-lived assets, goodwill and intangible assets (acquired in business combinations and analysis of impairment). Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. Property and Equipment As of March 31, 2023 and December 31, 2022, the Company’s gross carrying amount of property and equipment was $ 33.2 million and $ 29.5 million, with accumulated depreciation of $ 11.1 million and $ 9.4 million, respectively. For the three months ended March 31, 2023 and 2022, the Company recognized $ 1.7 million and $ 0.7 million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. Income Taxes The Company determined the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.

Revenue, Receivables, and Conce

Revenue, Receivables, and Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Revenue, Receivables, and Concentration of Credit Risk	NOTE 3. Revenue, Receivables, and Concentration of Credit Risk Medical Services Revenue Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. PMPM fees are determined as a percent of the premium payors receive from the Centers for Medicare & Medicaid Services’ (“CMS”) for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers. Receivables Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized. Concentration The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company’s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company’s total revenue for the three months ended March 31, 2023, and 2022. The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues: Three Months Ended 2023 2022 Payor A 23 % 25 % Payor B 16 % 19 % Payor C 15 % 14 % The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net: March 31, December 31, Payor A 14 % 13 % Payor B 17 % 20 % Payor C 14 % 10 % Payor D * 10 % Payor E * 11 % Payor F 12 % * * Less than 10 % of total receivables.

Marketable Securities and Fair

Marketable Securities and Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Debt Securities [Abstract]
Marketable Securities and Fair Value Measurements	NOTE 4. Marketable Secu rities and Fair Value Measurements Marketable Securities The following table summarizes the Company’s marketable securities (in thousands): March 31, 2023 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Marketable securities: Corporate debt securities $ 264,656 $ 235 $ ( 2,473 ) $ 262,418 $ 255,613 $ 60 $ ( 3,240 ) $ 252,433 U.S. Treasury notes 151,504 26 ( 1,399 ) 150,131 151,873 — ( 2,306 ) 149,567 Other 9,996 — ( 53 ) 9,943 9,975 — ( 74 ) 9,901 $ 426,156 $ 261 $ ( 3,925 ) $ 422,492 $ 417,461 $ 60 $ ( 5,620 ) $ 411,901 At March 31, 2023 and December 31, 2022, marketable securities of $ 380.6 million and $ 407.4 million, respectively, were in an unrealized loss position for less than twelve months. The Company’s unrealized losses from marketable securities as of March 31, 2023 and December 31, 2022 were caused primarily by interest rate increases. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Therefore, the Company believes these losses to be temporary. There was no allowance for credit losses on available-for-sale marketable securities at March 31, 2023 and December 31, 2022. The following table summarizes the Company’s marketable securities maturity as of March 31, 2023 (in thousands): Year Amortized Cost Fair Value 2023 $ 106,332 $ 105,734 2024 144,995 143,289 2025 162,986 161,654 2026 11,843 11,815 $ 426,156 $ 422,492 Fair Value Measurements The Company’s financial instruments consist of cash and cash equivalents, restricted cash and cash equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The Company may be required, from time to time, to measure its loans to physician partner groups in connection with taxes payable on shares distributed to them upon completion of the initial public offering ("IPO") at fair value on a nonrecurring basis. Such measurements are classified within Level 2 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three months ended March 31, 2023 and 2022, there were no material transfers of financial assets or liabilities within the fair value hierarchy. The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: • Level 1—quoted prices for identical instruments in active markets; • Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and • Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands): March 31, 2023 December 31, 2022 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Marketable securities: Corporate debt securities $ — $ 262,418 $ — $ — $ 252,433 $ — U.S. Treasury notes 150,131 — — 149,567 — — Other 9,943 — — 9,901 — — $ 160,074 $ 262,418 $ — $ 159,468 $ 252,433 $ —

Other Assets, net

Other Assets, net	3 Months Ended
	Mar. 31, 2023
Other Assets [Abstract]
Other Assets, net	NOTE 5. Other Assets, net The following table summarizes the Company’s other assets, net (in thousands): March 31, December 31, Loans to physician partners $ 65,596 $ 69,383 Health plan deposits 12,051 11,728 Equity method investments (1) 20,518 17,352 Right-of-use lease assets 13,893 13,029 Other 4,788 5,432 $ 116,846 $ 116,924 (1) See Note 14 for additional discussion related to the Company's equity method investments. Loans to Physician Partners The Company provided loans to its physician partners in connection with taxes payable on shares distributed to them in connection with the IPO . These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. Such loans are stated at the amount expected to be collected.

Medical Claims and Related Paya

Medical Claims and Related Payables	3 Months Ended
	Mar. 31, 2023
Insurance [Abstract]
Medical Claims and Related Payables	NOTE 6. Medical Claims and Related Payables Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and that are paid either directly by the Company or by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported. Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available. Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company’s medical claims payable balance represents management’s best estimate of its liability for unpaid medical costs as of March 31, 2023 and 2022. The Company uses judgment to determine the appropriate assumptions for developing the required estimates. The following table presents the components of changes in medical claims and related payables (in thousands): March 31, 2023 2022 Medical claims and related payables, beginning of the year $ 339,748 $ 239,014 Components of incurred costs related to: Current year 944,306 561,478 Prior years 28,521 4,730 Discontinued operations - prior years — ( 85 ) 972,827 566,123 Claims paid related to: Current year ( 258,217 ) ( 167,526 ) Prior years ( 320,828 ) ( 165,316 ) Discontinued operations - prior years — 28 ( 579,045 ) ( 332,814 ) Medical claims and related payables, end of the period $ 733,530 $ 472,323 Medical claims and related payables also include $ 12.0 million and $ 7.0 million, as of March 31, 2023 and December 31, 2022, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets. Medical claims and related payables presented in the periods above include immaterial balances related to claims liabilities associated with certain divested California businesses for which the Company has retained the liability for claims incurred prior to the date of divestiture.

Other Liabilities

Other Liabilities	3 Months Ended
	Mar. 31, 2023
Other Liabilities [Abstract]
Other Liabilities	NOTE 7. Other Liabilities The following table summarizes the Company’s other liabilities (in thousands): March 31, December 31, Other long-term contingencies $ 55,493 $ 62,931 Lease liabilities, long-term 10,473 9,885 Equity method liabilities – ACO REACH 5,146 4,657 Other 7,459 5,813 $ 78,571 $ 83,286 As of March 31, 2023 and December 31, 2022, the Company’s accruals for contingent liabilities related to unasserted claims were $ 55.5 million and $ 62.9 million, respectively. The accrued amounts represent the Company’s estimate of probable losses in accordance with ASC Topic 450, Contingencies . The Company’s estimate of the range of reasonably possible losses in excess of such accruals was $ 0 to $ 58.1 million as of March 31, 2023. See Note 14 for equity method liabilities related to the Company's ACO REACH investments.

Debt

Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt	NOTE 8. Debt On February 18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021, the “Credit Facilities”). The Credit Facilities include: (i) a $ 100.0 million secured term loan (the “Secured Term Loan Facility”) and (ii) a $ 100.0 million senior secured revolving credit facility (the “Secured Revolving Facility”) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $ 80.0 million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $ 50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company’s indebtedness. The maturity date of the Credit Facilities is February 18, 2026 . As of March 31, 2023, the Company had $ 42.5 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $ 38.2 million, as the Company had outstanding letters of credit totaling $ 61.8 million, of which $ 37.2 million was for the Company's ACO REACH investments. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of March 31, 2023. At the Company’s option, borrowings under the agreement can be either: (i) LIBO Rate Loans or (ii) Base Rate Loans. LIBO Rate Loans bear interest at a rate equal to the sum of 4.00 % (stepping down to 3.50 % on and following October 1, 2023) and the higher of (a) LIBO, as defined in the credit agreement, and (b) 0 %. Base Rate Loans bear interest at a rate equal to the sum of 3.00 % (stepping down to 2.50 % on and following October 1, 2023) and the highest of: (a) 0.50 % in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month LIBO rate (adjusted for maximum reserves) plus 1.00 % and (d) 0 %. Additionally, the Company pays a commitment fee on the unfunded 2021 Revolving Credit Facility amount of 0.50 % (s tepping down to 0.375 % on and following October 1, 2023). The Company must also pay customary letter of credit fees. As of March 31, 2023, the effective interest rate on the Secured Term Loan Facility was 9.218 %. The Credit Facilities are guaranteed by certain of the Company’s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the agreement to be immediately due and payable . As of March 31, 2023, the Company was in compliance with all covenants under the Credit Facilities .

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9. Commitments and Contingencies Legal Proceedings From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations or cash flows. The Company’s policy is to expense legal costs as they are incurred.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Common Stock	NOTE 10. Common Stock Common Stock 2023 . During the three months ended March 31, 2023, the Company issued approximately 2.1 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. 2022 . During the three months ended March 31, 2022, the Company issued approximately 5.6 million shares of common stock primarily in connection with exercises and vesting of stock-based awards.

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	NOTE 11. Net Income (Loss) Per Common Share Basic net income (loss) per common share (“EPS”) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic loss per share are included in diluted loss per share during the periods presented. The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts): Three Months Ended 2023 2022 Numerator Income (loss) from continuing operations $ 15,959 $ 726 Noncontrolling interests’ share in (earnings) loss from 63 75 Net income (loss) attributable to common stockholders 16,022 801 Income (loss) from discontinued operations — 429 Net income (loss) attributable to common stockholders $ 16,022 $ 1,230 Denominator Weighted average shares outstanding – basic 413,136 401,964 Weighted average shares outstanding – diluted 426,586 424,065 Net income (loss) per share attributable to Net income (loss) per common share from $ 0.04 $ — Net income (loss) per common share from $ — $ — The following table provides the weighted-average potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands): Three Months Ended 2023 2022 Stock options - service only condition 2,098 1,503 Equity awards - market and/or performance condition 4,570 909 Restricted stock units 22 89

Goodwill and Amortizable Intang

Goodwill and Amortizable Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Amortizable Intangible Assets	NOTE 12. Goodwill and Amortizable Intangible Assets As of March 31, 2023 and December 31, 2022, the Company’s goodwill balance was $ 62.1 million and $ 41.5 million, respectively, of which $ 39.0 million was allocated to the Company’s Hawaii reporting unit, which had a negative carrying value. As of March 31, 2023 and December 31, 2022, the Company’s gross carrying amount of amortizable intangible assets was $ 158.3 million and $ 130.8 million, with accumulated amortization of $ 65.6 million and $ 63.1 million, respectively. For the three months ended March 31, 2023 and 2022, the Company recognized $ 2.5 million and $ 2.7 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. Acquisition On February 28, 2023, the Company completed the acquisition of My Personal Health Record Express, Inc.(the “Acquisition”), a leading provider of value-based care technology and interoperability solutions for cash consideration of $ 44.4 million, net of cash acquired and subject to certain post-closing adjustments. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including other intangible assets and deferred taxes, requires significant judgment. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, the Company estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within the Company's consolidated results of operations. The following preliminary allocation of the purchase price related to the Acquisition based upon the fair value of assets and liabilities assumed included developed technology intangible assets of $ 25.6 million, customer relationship intangible assets of $ 1.9 million, and assumed net liabilities of $ 3.7 million, with the residual amount being recorded as goodwill of $ 20.6 million. The intangible assets acquired have a weighted-average life of 10 years.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	NOTE 13. Supplemental Cash Flow Information The following table provides supplemental cash flow information (in thousands): Three Months Ended 2023 2022 Supplemental cash flow information: Interest paid $ 1,352 $ 959 Income taxes paid 171 3,098 Supplemental disclosure of non-cash investing and financing activities: Right-of-use asset obtained in exchange for new operating lease liability 435 1,178 Non-cash investment in unconsolidated subsidiaries — 190 The following table summarizes cash, cash equivalents and restricted cash equivalents from continuing operations (in thousands): March 31, December 31, Cash and cash equivalents $ 394,190 $ 497,070 Restricted cash and equivalents (1) 10,204 10,610 Cash, cash equivalents and restricted cash equivalents $ 404,394 $ 507,680 (1) Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2023
Variable Interest Entities [Abstract]
Variable Interest Entities	NOTE 14. Variable Interest Entities Consolidated Variable Interest Entities agilon health, inc.’s consolidated assets and liabilities as of March 31, 2023 and December 31, 2022 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc. agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands): March 31, December 31, Assets Cash and cash equivalents $ 99,767 $ 155,819 Restricted cash equivalents 10,204 10,610 Receivables, net 989,483 492,077 Prepaid expenses and other current assets, net 23,733 15,515 Property and equipment, net 1,782 1,567 Intangible assets, net 43,631 17,347 Other assets, net 11,571 10,371 Liabilities Medical claims and related payables 701,238 300,798 Accounts payable and accrued expenses 190,691 159,526 Other liabilities 5,771 2,059 Risk-bearing Entities. At March 31, 2023, the Company operates 28 wholly-owned risk-bearing entities (“RBEs”) for the purpose of entering into risk-bearing contracts with payors. Each RBE’s equity at risk is considered insufficient to finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs’ economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs’ annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets, net; its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company’s physician partners. On February 18, 2021, the Company executed the Credit Facilities, which are guaranteed by certain of the Company’s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company’s contractual debt obligations. Unconsolidated Variable Interest Entities As of March 31, 2023, the Company had nine equity method investments (liabilities) that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party’s control of the VIEs’ board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company's maximum loss exposure as a result of the Company’s involvement with the VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed. Equity Method Investments The following table summarizes the Company’s equity method investments (in thousands): March 31, December 31, Equity method investments - Other (1) $ 8,371 $ 8,329 Equity method investments - ACO REACH (1) 12,147 9,023 Equity method liabilities - ACO REACH (2) ( 5,146 ) ( 4,657 ) (1) Included in Other assets, net in the condensed consolidated balance sheets. (2) Included in Other liabilities in the condensed consolidated balance sheets. The Company is a partner in eight wholly-owned ACO REACH entities in collaboration with 12 of its physician group partners operating in 10 geographies. The combined summarized operating results of the Company’s ACO REACH entities are as follows (in thousands): Three Months Ended 2023 2022 Medical services revenue $ 280,529 $ 267,713 Medical services expense ( 257,477 ) ( 248,351 ) Other medical expenses (1) ( 15,744 ) ( 12,644 ) Income (loss) from operations 2,001 3,183 Net income (loss) (2) 1,334 2,012 (1) For the three months ended March 31, 2023 and 2022, includes physician incentive expenses of $ 9.7 million and $ 6.2 million, respectively. (2) Included in Other income (expense) in the condensed consolidated statements of operations. The combined summarized balance sheet of the Company’s ACO REACH entities are as follows (in thousands): March 31, December 31, Current and total assets $ 84,691 $ 70,625 Current and total liabilities 78,774 67,343

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and both joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Use of Estimates	Use of Estimates Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (“IBNR”) claims), and valuation of long-lived assets, goodwill and intangible assets (acquired in business combinations and analysis of impairment). Management’s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.
Property and Equipment	Property and Equipment As of March 31, 2023 and December 31, 2022, the Company’s gross carrying amount of property and equipment was $ 33.2 million and $ 29.5 million, with accumulated depreciation of $ 11.1 million and $ 9.4 million, respectively. For the three months ended March 31, 2023 and 2022, the Company recognized $ 1.7 million and $ 0.7 million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.
Income Taxes	Income Taxes The Company determined the income tax provision for interim periods using an estimate of the Company’s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.
Medical Services Revenue	Medical Services Revenue Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (“payors”). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (“PMPM”) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (“members”) attributed to the Company’s contracted primary care physicians. PMPM fees are determined as a percent of the premium payors receive from the Centers for Medicare & Medicaid Services’ (“CMS”) for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers (“ASC 606”), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The transaction price for the Company’s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS’s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member’s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company’s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.
Receivables	Receivables Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management’s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.

Revenue, Receivables, and Con_2

Revenue, Receivables, and Concentration of Credit Risk (Tables)	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk as a Percentage of Revenues and Receivables	The following table provides the Company’s revenue concentration with respect to major payors as a percentage of the Company’s total revenues: Three Months Ended 2023 2022 Payor A 23 % 25 % Payor B 16 % 19 % Payor C 15 % 14 % The following table provides the Company’s concentration of credit risk with respect to major payors as a percentage of receivables, net: March 31, December 31, Payor A 14 % 13 % Payor B 17 % 20 % Payor C 14 % 10 % Payor D * 10 % Payor E * 11 % Payor F 12 % * * Less than 10 % of total receivables.

Marketable Securities and Fai_2

Marketable Securities and Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Securities [Abstract]
Summary of Marketable Securities	The following table summarizes the Company’s marketable securities (in thousands): March 31, 2023 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Marketable securities: Corporate debt securities $ 264,656 $ 235 $ ( 2,473 ) $ 262,418 $ 255,613 $ 60 $ ( 3,240 ) $ 252,433 U.S. Treasury notes 151,504 26 ( 1,399 ) 150,131 151,873 — ( 2,306 ) 149,567 Other 9,996 — ( 53 ) 9,943 9,975 — ( 74 ) 9,901 $ 426,156 $ 261 $ ( 3,925 ) $ 422,492 $ 417,461 $ 60 $ ( 5,620 ) $ 411,901
Summarizes Marketable Securities Maturity Table Text Block	The following table summarizes the Company’s marketable securities maturity as of March 31, 2023 (in thousands): Year Amortized Cost Fair Value 2023 $ 106,332 $ 105,734 2024 144,995 143,289 2025 162,986 161,654 2026 11,843 11,815 $ 426,156 $ 422,492
Summary of Fair Value Assets Measured on Recurring Basis	The table below summarizes the Company’s financial instruments measured at fair value on a recurring basis (in thousands): March 31, 2023 December 31, 2022 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Marketable securities: Corporate debt securities $ — $ 262,418 $ — $ — $ 252,433 $ — U.S. Treasury notes 150,131 — — 149,567 — — Other 9,943 — — 9,901 — — $ 160,074 $ 262,418 $ — $ 159,468 $ 252,433 $ —

Other Assets, net (Tables)

Other Assets, net (Tables)	3 Months Ended
	Mar. 31, 2023
Other Assets [Abstract]
Schedule of Other Assets, Net	The following table summarizes the Company’s other assets, net (in thousands): March 31, December 31, Loans to physician partners $ 65,596 $ 69,383 Health plan deposits 12,051 11,728 Equity method investments (1) 20,518 17,352 Right-of-use lease assets 13,893 13,029 Other 4,788 5,432 $ 116,846 $ 116,924 (1) See Note 14 for additional discussion related to the Company's equity method investments.

Medical Claims and Related Pa_2

Medical Claims and Related Payables (Tables)	3 Months Ended
	Mar. 31, 2023
Insurance [Abstract]
Summary Changes in Medical Claims and Related Payables	The following table presents the components of changes in medical claims and related payables (in thousands): March 31, 2023 2022 Medical claims and related payables, beginning of the year $ 339,748 $ 239,014 Components of incurred costs related to: Current year 944,306 561,478 Prior years 28,521 4,730 Discontinued operations - prior years — ( 85 ) 972,827 566,123 Claims paid related to: Current year ( 258,217 ) ( 167,526 ) Prior years ( 320,828 ) ( 165,316 ) Discontinued operations - prior years — 28 ( 579,045 ) ( 332,814 ) Medical claims and related payables, end of the period $ 733,530 $ 472,323

Other Liabilities (Tables)

Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Other Liabilities [Abstract]
Summary of Other Liabilities	The following table summarizes the Company’s other liabilities (in thousands): March 31, December 31, Other long-term contingencies $ 55,493 $ 62,931 Lease liabilities, long-term 10,473 9,885 Equity method liabilities – ACO REACH 5,146 4,657 Other 7,459 5,813 $ 78,571 $ 83,286

Net Income (Loss) Per Common _2

Net Income (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Summery Of Net income(loss) Per Share Attributable To Common Stockholder	The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts): Three Months Ended 2023 2022 Numerator Income (loss) from continuing operations $ 15,959 $ 726 Noncontrolling interests’ share in (earnings) loss from 63 75 Net income (loss) attributable to common stockholders 16,022 801 Income (loss) from discontinued operations — 429 Net income (loss) attributable to common stockholders $ 16,022 $ 1,230 Denominator Weighted average shares outstanding – basic 413,136 401,964 Weighted average shares outstanding – diluted 426,586 424,065 Net income (loss) per share attributable to Net income (loss) per common share from $ 0.04 $ — Net income (loss) per common share from $ — $ —
Summary of Weighted-average Potential Shares of Common Stock Were Excluded From Calculation of Diluted Net Income (Loss) Per Share Attributable to Common Stockholders	The following table provides the weighted-average potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands): Three Months Ended 2023 2022 Stock options - service only condition 2,098 1,503 Equity awards - market and/or performance condition 4,570 909 Restricted stock units 22 89

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Summary of Supplemental Cash Flow Information	The following table provides supplemental cash flow information (in thousands): Three Months Ended 2023 2022 Supplemental cash flow information: Interest paid $ 1,352 $ 959 Income taxes paid 171 3,098 Supplemental disclosure of non-cash investing and financing activities: Right-of-use asset obtained in exchange for new operating lease liability 435 1,178 Non-cash investment in unconsolidated subsidiaries — 190
Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations	The following table summarizes cash, cash equivalents and restricted cash equivalents from continuing operations (in thousands): March 31, December 31, Cash and cash equivalents $ 394,190 $ 497,070 Restricted cash and equivalents (1) 10,204 10,610 Cash, cash equivalents and restricted cash equivalents $ 404,394 $ 507,680 (1) Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	3 Months Ended
	Mar. 31, 2023
Variable Interest Entities [Abstract]
Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities	agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands): March 31, December 31, Assets Cash and cash equivalents $ 99,767 $ 155,819 Restricted cash equivalents 10,204 10,610 Receivables, net 989,483 492,077 Prepaid expenses and other current assets, net 23,733 15,515 Property and equipment, net 1,782 1,567 Intangible assets, net 43,631 17,347 Other assets, net 11,571 10,371 Liabilities Medical claims and related payables 701,238 300,798 Accounts payable and accrued expenses 190,691 159,526 Other liabilities 5,771 2,059
Schedule of Equity Method Investments	The following table summarizes the Company’s equity method investments (in thousands): March 31, December 31, Equity method investments - Other (1) $ 8,371 $ 8,329 Equity method investments - ACO REACH (1) 12,147 9,023 Equity method liabilities - ACO REACH (2) ( 5,146 ) ( 4,657 ) (1) Included in Other assets, net in the condensed consolidated balance sheets. (2) Included in Other liabilities in the condensed consolidated balance sheets.
Summary of Operating Results	The combined summarized operating results of the Company’s ACO REACH entities are as follows (in thousands): Three Months Ended 2023 2022 Medical services revenue $ 280,529 $ 267,713 Medical services expense ( 257,477 ) ( 248,351 ) Other medical expenses (1) ( 15,744 ) ( 12,644 ) Income (loss) from operations 2,001 3,183 Net income (loss) (2) 1,334 2,012 (1) For the three months ended March 31, 2023 and 2022, includes physician incentive expenses of $ 9.7 million and $ 6.2 million, respectively. (2) Included in Other income (expense) in the condensed consolidated statements of operations.
Summarized balance sheet	The combined summarized balance sheet of the Company’s ACO REACH entities are as follows (in thousands): March 31, December 31, Current and total assets $ 84,691 $ 70,625 Current and total liabilities 78,774 67,343

Business - Additional Informati

Business - Additional Information (Details)	Mar. 31, 2023 Medicare
Description of Business [Line Items]
Number of medicare advantage members enrolled with private health plans	402,200

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items]
Gross carrying amount of property and equipment	$ 33.2		$ 29.5
Accumulated amortization	11.1		$ 9.4
Depreciation expense	$ 1.7	$ 0.7

Revenue, Receivables, and Con_3

Revenue, Receivables, and Concentration of Credit Risk - Schedules of Concentration of Risk as a Percentage of Revenues and Receivables (Details) - Major Payors	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Total Revenues | Payor A
Concentration Risk [Line Items]
Concentration risk, percentage	23%	25%
Total Revenues | Payor B
Concentration Risk [Line Items]
Concentration risk, percentage	16%	19%
Total Revenues | Payor C
Concentration Risk [Line Items]
Concentration risk, percentage	15%	14%
Receivables | Payor A
Concentration Risk [Line Items]
Concentration risk, percentage	14%		13%
Receivables | Payor B
Concentration Risk [Line Items]
Concentration risk, percentage	17%		20%
Receivables | Payor C
Concentration Risk [Line Items]
Concentration risk, percentage	14%		10%
Receivables | Payor D
Concentration Risk [Line Items]
Concentration risk, percentage			10%
Receivables | Payor E
Concentration Risk [Line Items]
Concentration risk, percentage			11%
Receivables | Payor F
Concentration Risk [Line Items]
Concentration risk, percentage	12%

Revenue, Receivables, and Con_4

Revenue, Receivables, and Concentration of Credit Risk - Schedules of Concentration of Risk as a Percentage of Revenues and Receivables (Parenthetical) (Details) - Maximum [Member] - Receivables	3 Months Ended
	Mar. 31, 2023
Payor D
Concentration Risk [Line Items]
Concentration risk, percentage	10%
Payor E
Concentration Risk [Line Items]
Concentration risk, percentage	10%
Payor F
Concentration Risk [Line Items]
Concentration risk, percentage	10%

Marketable Securities and Fai_3

Marketable Securities and Fair Value Measurements - Summary of Marketable Securities (Details) - Marketable securities [Member] - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Marketable debt securities [Line Items]
Amortized Cost	$ 426,156	$ 417,461
Gross Unrealized Gains	261	60
Gross Unrealized Losses	(3,925)	(5,620)
Fair value	422,492	411,901
Corporate Debt Securities [Member]
Marketable debt securities [Line Items]
Amortized Cost	264,656	255,613
Gross Unrealized Gains	235	60
Gross Unrealized Losses	(2,473)	(3,240)
Fair value	262,418	252,433
U.S. Treasury notes [Member]
Marketable debt securities [Line Items]
Amortized Cost	151,504	151,873
Gross Unrealized Gains	26	0
Gross Unrealized Losses	(1,399)	(2,306)
Fair value	150,131	149,567
Other [Member]
Marketable debt securities [Line Items]
Amortized Cost	9,996	9,975
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(53)	(74)
Fair value	$ 9,943	$ 9,901

Marketable Securities and Fai_4

Marketable Securities and Fair Value Measurements - Summarizes Marketable Securities Maturity (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Debt Securities [Abstract]
2023	$ 106,332
2024	144,995
2025	162,986
2026	11,843
Amortized Cost, Total	426,156
2023	105,734
2024	143,289
2025	161,654
2026	11,815
Fair Value Total	$ 422,492

Marketable Securities and Fai_5

Marketable Securities and Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Level 1 [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	$ 160,074	$ 159,468
Level 2 [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	262,418	252,433
Level 3 [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	0	0
Corporate Debt Securities [Member] | Level 1 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	0	0
Corporate Debt Securities [Member] | Level 2 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	262,418	252,433
Corporate Debt Securities [Member] | Level 3 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	0	0
U.S. Treasury notes [Member] | Level 1 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	150,131	149,567
U.S. Treasury notes [Member] | Level 2 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	0	0
U.S. Treasury notes [Member] | Level 3 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	0	0
Other [Member] | Level 1 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	9,943	9,901
Other [Member] | Level 2 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	0	0
Other [Member] | Level 3 [Member] | Marketable securities [Member]
Marketable debt securities [Line Items]
Fair Value Disclosure	$ 0	$ 0

Marketable Securities and Fai_6

Marketable Securities and Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Gain (Loss) on Securities [Line Items]
Marketable securities in an unrealized loss position for less than twelve months	$ 380,600	$ 407,400
Allowances for credit losses	$ 0	$ 0

Other Assets, net - Schedule of

Other Assets, net - Schedule of Other Assets, Net (Details) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Other Assets [Line Items]
Other assets, net		$ 116,846	$ 116,924
Equity method investments		5,146	4,657
Loans to Physician Partners
Other Assets [Line Items]
Other assets, net		65,596	69,383
Health Plan Deposits
Other Assets [Line Items]
Other assets, net		12,051	11,728
Right-Of-Use Assets
Other Assets [Line Items]
Other assets, net		13,893	13,029
Other
Other Assets [Line Items]
Other assets, net		4,788	5,432
Equity Method Investments
Other Assets [Line Items]
Other assets, net	[1]	$ 20,518	$ 17,352
[1] See Note 14 for additional discussion related to the Company's equity method investments.

Medical Claims and Related Pa_3

Medical Claims and Related Payables - Summary Changes in Medical Claims and Related Payables (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Liability For Claims And Claims Adjustment Expense [Line Items]
Medical claims and related payables, beginning of the year	$ 346,727
Claims paid related to:
Medical claims and related payables, end of the period	745,557
Medical Claims and Related Payables
Liability For Claims And Claims Adjustment Expense [Line Items]
Medical claims and related payables, beginning of the year	339,748	$ 239,014
Components of incurred costs related to:
Current year	944,306	561,478
Prior years	28,521	4,730
Discontinued operations - prior years	(28,521)	(4,730)
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims	972,827	566,123
Claims paid related to:
Current year	(258,217)	(167,526)
Prior years	(320,828)	(165,316)
Discontinued operations - prior years	320,828	165,316
Claims paid related	(579,045)	(332,814)
Medical claims and related payables, end of the period	733,530	472,323
Discontinued Operations | Medical Claims and Related Payables
Components of incurred costs related to:
Prior years	0	(85)
Discontinued operations - prior years	0	85
Claims paid related to:
Prior years	0	(28)
Discontinued operations - prior years	$ 0	$ 28

Medical Claims and Related Pa_4

Medical Claims and Related Payables (Additional Information) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current Liabilities Held For Sale And Discontinued Operations
Liability for Claims and Claims Adjustment Expense [Line Items]
Related payables associated with retained liability	$ 12	$ 7

Other Liabilities - Summary of

Other Liabilities - Summary of Other Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Other Liabilities [Line Items]
Other long-term contingencies	$ 55,493	$ 62,931
Lease liabilities, long-term	$ 10,473	$ 9,885
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Equity method liabilities - ACO REACH	$ 5,146	$ 4,657
Other	7,459	5,813
Other liabilities	$ 78,571	$ 83,286

Other Liabilities - Additional

Other Liabilities - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Other Liabilities [Line Items]
Other long-term contingencies	$ 55,493	$ 62,931
Unasserted Claim [Member]
Other Liabilities [Line Items]
Other long-term contingencies	55,500	$ 62,900
Minimum [Member]
Other Liabilities [Line Items]
Estimated range of reasonably possible losses in excess of reserves accrued	0
Maximum [Member]
Other Liabilities [Line Items]
Estimated range of reasonably possible losses in excess of reserves accrued	$ 58,100

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)				3 Months Ended
	Oct. 01, 2023	Apr. 26, 2021	Feb. 18, 2021	Mar. 31, 2023	Mar. 31, 2022
Debt Instrument [Line Items]
Refinance of aggregate outstanding indebtedness				$ 1,250,000	$ 1,250,000
2021 Secured Term Loan Facility
Debt Instrument [Line Items]
Maturity date		Feb. 18, 2026
Weighted average effective interest rate				9.218%
2021 Secured Revolving Facility | Unfunded Loan Commitment
Debt Instrument [Line Items]
Percentage of commitment fee				0.50%
2021 Secured Revolving Facility | Forecast | Unfunded Loan Commitment
Debt Instrument [Line Items]
Percentage of commitment fee	0.375%
Standby Letters of Credit
Debt Instrument [Line Items]
Credit facility remaining borrowing capacity			$ 80,000,000
Total outstanding letters of credit				$ 61,800,000
Extended term of letters of credit				1 year
Outstanding letters of credit, amount drawn				$ 0
Credit Facilities
Debt Instrument [Line Items]
Credit facility, covenant terms, description				Failure to meet any of these covenants could result in an event of default under the agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the agreement to be immediately due and payable
Credit facility, covenant compliance				As of March 31, 2023, the Company was in compliance with all covenants under the Credit Facilities.
Credit Facilities | LIBO
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				0%
Credit Facilities | LIBO | Forecast
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	3.50%
Credit Facilities | LIBO | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				4%
Credit Facilities | Base Rate Loans
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				0%
Credit Facilities | Base Rate Loans | Forecast
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.50%
Credit Facilities | Base Rate Loans | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				3%
Credit Facilities | Overnight Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				0.50%
Credit Facilities | One-month LIBO Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				1%
Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Credit facility remaining borrowing capacity			100,000,000
Increase in amount of credit facility			50,000,000
Credit facility amount outstanding				$ 42,500,000
Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility remaining borrowing capacity			$ 100,000,000
Credit facility amount outstanding				38,200,000
DCE Investment | Standby Letters of Credit
Debt Instrument [Line Items]
Total outstanding letters of credit				$ 37,200,000

Common Stock - Additional Infor

Common Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Subsidiary Sale Of Stock [Line Items]
Common stock, authorized capital stock	2,000,000,000		2,000,000,000
Common stock, shares issued	414,465,000		412,385,000
Recognized stock-based compensation expense	$ 13,672	$ 3,970
Common stock, par value	$ 0.01		$ 0.01
Number of shares issued under share-based awards	2,100,000	5,600,000

Net Income (Loss) Per Common _3

Net Income (Loss) Per Common Share - Computation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator
Income (loss) from continuing operations	$ 15,959	$ 726
Noncontrolling interests' share in (earnings) loss from continuing operations	63	75
Net income (loss) attributable to common stockholders before discontinued operations	16,022	801
Income (loss) from discontinued operations	0	429
Net income (loss) attributable to common shares	$ 16,022	$ 1,230
Denominator
Weighted average shares outstanding - basic	413,136	401,964
Weighted average shares outstanding - diluted	426,586	424,065
Net income (loss) per share attributable to common stockholders
Net income (loss) per common share from continuing operations, basic	$ 0.04	$ 0
Net income (loss) per common share from continuing operations, diluted	0.04	0
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share	0	0
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share	$ 0	$ 0

Net Income (Loss) Per Common _4

Net Income (Loss) Per Common Share - Summary of Weighted-average Potential Shares of Common Stock Were Excluded From Calculation of Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock Options - Service Only Condition
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,098	1,503
Equity Awards - Market and/or Performance Condition
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,570	909
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	22	89

Goodwill and Amortizable Inta_2

Goodwill and Amortizable Intangible Assets (Additional Information) (Details) - USD ($) $ in Thousands		3 Months Ended
	Feb. 28, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Indefinite-Lived Intangible Assets [Line Items]
Goodwill		$ 62,140		$ 41,540
Gross carrying amount of amortizable intangible assets		158,300		130,800
Accumulated amortization		65,600		63,100
Amortization expense		2,500	$ 2,700
Weighted-average life	10 years
mphrX [Member]
Indefinite-Lived Intangible Assets [Line Items]
Business Combination, Consideration Transferred	$ 44,400
mphrX [Member] | Developed Technology [Member]
Indefinite-Lived Intangible Assets [Line Items]
Assets acquired	25,600
mphrX [Member] | Customer Relationships [Member]
Indefinite-Lived Intangible Assets [Line Items]
Goodwill	20,600
Net liabilities assumed	3,700
Assets acquired	$ 1,900
Hawaii Reporting Unit [Member]
Indefinite-Lived Intangible Assets [Line Items]
Goodwill		$ 39,000		$ 39,000

Discontinued Operations - Summa

Discontinued Operations - Summary of Results of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Total discontinued operations	$ 0	$ 429

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Supplemental cash flow information:
Interest paid	$ 1,352	$ 959
Income taxes paid	171	3,098
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use asset obtained in exchange for new operating lease liability	435	1,178
Non-cash investment in unconsolidated subsidiaries	$ 0	$ 190

Supplemental Cash Flow Inform_4

Supplemental Cash Flow Information - Summary of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Cash and cash equivalents		$ 394,190	$ 497,070
Restricted cash and equivalents	[1]	10,204	10,610
Cash, cash equivalents and restricted cash equivalents		$ 404,394	$ 507,680
[1] Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.

Variable Interest Entities - Su

Variable Interest Entities - Summary of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 394,190	$ 497,070
Receivables, net	1,004,856	497,574
Prepaid expenses and other current assets, net	44,697	34,119
Property and equipment, net	22,132	20,050
Intangible assets, net	92,712	67,680
Liabilities
Medical claims and related payables	745,557	346,727
Accounts payable and accrued expenses	222,052	183,364
Variable Interest Entity
ASSETS
Cash and cash equivalents	99,767	155,819
Restricted cash equivalents	10,204	10,610
Receivables, net	989,483	492,077
Prepaid expenses and other current assets, net	23,733	15,515
Property and equipment, net	1,782	1,567
Intangible assets, net	43,631	17,347
Other assets, net	11,571	10,371
Liabilities
Medical claims and related payables	701,238	300,798
Accounts payable and accrued expenses	190,691	159,526
Other liabilities	$ 5,771	$ 2,059

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023 Physician Entity Geographies Equity
Variable Interest Entity [Line Items]
Number of geographies | Geographies	10
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of wholly-owned risk-bearing entities	28
Variable interest entity, methodology for determining whether Entity is primary beneficiary	The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs’ economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs’ annual operating budgets.
Number of Direct Contracting Entities	8
Number of physician group partners | Physician	12
Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Number of equity method investments for VIEs | Equity	9

Variable Interest Entities - Sc

Variable Interest Entities - Schedule of Equity Method Investments (Details) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Other Assets | Equity Method Investments
Schedule Of Equity Method Investments [Line Items]
Equity method investments	[1]	$ 8,371	$ 8,329
Other Assets | Direct Contracting Entities [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investments	[1]	12,147	9,023
Other Liabilities | Direct Contracting Entities [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investments	[2]	$ (5,146)	$ (4,657)
[1] Included in Other assets, net in the condensed consolidated balance sheets. Included in Other liabilities in the condensed consolidated balance sheets.

Variable Interest Entities - _2

Variable Interest Entities - Summary of Operating Results (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Subsidiary or Equity Method Investee [Line Items]
Total revenues		$ 1,136,147	$ 653,445
Medical services expense		(972,827)	(566,208)
Other medical expenses		86,024	44,773
Income (loss) from operations		6,261	(743)
Net income (loss)		16,022	1,230
Medical Services Revenue
Subsidiary or Equity Method Investee [Line Items]
Total revenues		1,134,830	652,423
Direct Contracting Entities [Member]
Subsidiary or Equity Method Investee [Line Items]
Medical services expense		(257,477)	(248,351)
Other medical expenses	[1]	(15,744)	(12,644)
Income (loss) from operations		2,001	3,183
Net income (loss)	[2]	1,334	2,012
Direct Contracting Entities [Member] | Medical Services Revenue
Subsidiary or Equity Method Investee [Line Items]
Total revenues		$ 280,529	$ 267,713
[1] For the three months ended March 31, 2023 and 2022, includes physician incentive expenses of $ 9.7 million and $ 6.2 million, respectively. Included in Other income (expense) in the condensed consolidated statements of operations.

Variable Interest Entities - _3

Variable Interest Entities - Summary of Operating Results (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Other Assets [Abstract]
Physician Compensation Expense	$ 9.7	$ 6.2

Variable Interest Entities - _4

Variable Interest Entities - Summarized balance sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current and total assets	$ 2,170,269	$ 1,697,468
Current and total liabilities	1,088,429	656,859
Direct Contracting Entities [Member]
Current and total assets	84,691	70,625
Current and total liabilities	$ 78,774	$ 67,343